Kingchem Life Science 金凯生科
2 significant filings since 31 May 2026: 1 on major holder selling and 1 on equity incentive. The latest, on 15 Sep 2026: 关于股东减持股份计划期间届满暨减持结果的公告.
自 31 May 2026 起有 2 份重大公告：major holder selling 1 份、equity incentive 1 份。最新一份（15 Sep 2026）：关于股东减持股份计划期间届满暨减持结果的公告。
Price History 价格走势
5 sessions 个交易日, 21 Sep to 28 Sep 2026 · Live one-minute prices 实时分钟价格 · High 最高 ¥33.04 · Low 最低 ¥29.93 · −1.25% on the previous close of ¥31.19 较昨收As of 25 Sep 2026 截至2026年9月25日
Kingchem Life Science 金凯生科 is a healthcare services company listed on the Shenzhen Stock Exchange since 3 Aug 2023. The company reported strong growth in 2025, with revenue rising to RMB639.4m from RMB497.0m in 2024, and attributable net profit increasing to RMB104.8m from RMB38.6m. Profit quality is supported by operating cash flow of RMB1.41 per share, exceeding net profit, with a cash-to-profit ratio of 1.62x. As of 30 Jun 2026, the balance sheet remains robust, with a low liabilities-to-assets ratio of 6.5% and strong liquidity, reflected in a current ratio of 13.39. However, the first half of 2026 showed a decline, with revenue down 11.2% and profit down 57.8% year-on-year. The stock has declined 11.1% over one year, with four volatile trading days in the past 12 months. Receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, and segment revenue are not shown.
金凯生科是一家医疗服务公司，于2023年8月3日在深圳证券交易所上市。公司2025年业绩表现强劲，营业收入从2024年的4.97亿元增至6.39亿元，归母净利润从3,860.9万元增至1.05亿元。每股经营现金流达1.41元，超过净利润，经营现金流与净利润之比为1.62倍，显示盈利质量良好。截至2026年6月30日，资产负债率为6.5%，流动比率13.39，流动性充裕。但2026年上半年出现下滑，营业收入同比减少11.2%，归母净利润减少57.8%。过去一年股价下跌11.1%，近12个月有4个交易日波动超9%。应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入未列示。
- Change in attributable net profit for the full year 2026 compared to 2025
2026全年归母净利润相较2025年的变动 - Revenue trend in the second half of 2026 versus the first half
2026年下半年营业收入相较上半年的趋势 - Operating cash flow per share for the full year 2026
2026全年每股经营现金流 - Liabilities to assets ratio at year-end 2026
2026年末资产负债率 - Next shareholder distribution announcement
下一次股东分红公告 - Update on receivable days and inventory days as of 31 Dec 2026
截至2026年12月31日的应收账款周转天数和存货周转天数更新
- Company: Kingchem Life Science 金凯生科, Shenzhen Stock Exchange 301509; industry Healthcare Services; listed 3 Aug 2023.
公司：金凯生科，深圳证券交易所 301509；行业：医疗服务；上市日期：2023年8月3日。 - Close on 24 Sep 2026 RMB31.19; close on 24 Sep 2025 RMB36.17, RMB35.08 in today's terms; one-year change, adjusted for distributions and share changes -11.1%.
2026年9月24日收盘价31.19元；2025年9月24日收盘价36.17元（前复权35.08元）；一年涨跌幅（复权）-11.1%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB26.19 to RMB45.74.
52周区间（前复权）26.19元至45.74元。 - In the last 12 months 4 trading days closed 9% or more above or below the day before (all days, not only this year). The 4 most recent of them: 24 Mar 2026 +9.3%; 27 Apr 2026 -12.6%; 29 Jun 2026 +10.0%; 7 Aug 2026 +9.9%. No two of the 4 fell on consecutive trading days.
近12个月共有4个交易日收盘涨跌幅达9%及以上（为全部交易日，不限于今年）。其中最近4个：2026年3月24日 +9.3%；2026年4月27日 -12.6%；2026年6月29日 +10.0%；2026年8月7日 +9.9%。其中任意两个交易日均不相邻。 - Market capitalisation RMB3.76bn; P/E TTM 59.3; price to book 1.77x.
总市值37.57亿元；市盈率（TTM）59.3；市净率1.77倍。 - Revenue 2025 RMB639.4m; 2024 RMB497.0m; change +28.6%.
营业收入2025年6.39亿元；2024年4.97亿元；同比+28.6%。 - Attributable net profit 2025 RMB104.8m; 2024 RMB38.6m; change +171.5%.
归属于母公司股东的净利润2025年1.05亿元；2024年3,860.9万元；同比+171.5%。 - Net profit excluding non-recurring items, 2025 change +374.4%.
2025年扣除非经常性损益后的净利润同比+374.4%。 - Basic EPS 2025 RMB0.87; 2024 RMB0.32.
基本每股收益2025年0.87元；2024年0.32元。 - Operating cash flow per share 2025 RMB1.41; 2024 RMB1.29; operating cash flow to net profit 1.62x.
每股经营现金流2025年1.41元；2024年1.29元；经营现金流与净利润之比1.62倍。 - 2025 gross margin 42.5%; net margin 16.4%; ROE 4.8%.
2025年毛利率42.5%；净利率16.4%；净资产收益率4.8%。 - At 30 Jun 2026: liabilities to assets 6.5%; current ratio 13.39; quick ratio 12.14; receivable days 62; inventory days 146.
截至2026年6月30日：资产负债率6.5%；流动比率13.39；速动比率12.14；应收账款周转天数62；存货周转天数146。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB309.3m, change -11.2%; attributable net profit RMB30.3m, change -57.8%; operating cash flow per share RMB0.37.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入3.09亿元，同比-11.2%；归母净利润3,027.2万元，同比-57.8%；每股经营现金流0.37元。 - Ownership: controlling shareholder Kingchem (China) Holding LLC; actual controller Fumin Wang(王富民),Lianping Wu(吴连萍); largest holder at 30 Jun 2026: Kingchem(China)Holding LLC, 48.66%.
股权：控股股东：Kingchem (China) Holding LLC；实际控制人：Fumin Wang(王富民),Lianping Wu(吴连萍)；2026年6月30日第一大股东：Kingchem(China)Holding LLC，持股48.66%。 - Latest distribution: ex-date 2 Jun 2026, cash RMB0.90 per share.
最近一次分配：除权除息日2026年6月2日，每股现金0.90元。 - Aurelian Grade C, score 57.7 of 100, graded within a peer group of 54 companies in its industry; no rank among peers is given.
金源评级C，得分57.7（满分100），于行业同业54家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。